Krystal Biotech (KRYS) Stock Forecast & Price Target

Krystal Biotech is poised for continued growth with their strong platform in dermatology, diverse pipeline, and potential for international expansion. Their promising first drug, Vyjuvek, and development of gene therapies for rare diseases and cystic fibrosis, coupled with potential success in their NK program and clinical trials, make them a strong investment option in the biotech industry. However, potential risks in the industry, as well as the success of their inhaled immunotherapy, KB707, and discussions for FDA approval, should be considered when analyzing their stock value.

Krystal Biotech is a commercial-stage biotechnology company that utilizes its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. However, their lead product, VYJUVEK, may face challenges in the market due to potential competition from other AAV gene therapy companies and skepticism about its efficacy and dosing convenience. The slow enrollment in their clinical studies could also be problematic in the long run, and their cash flow positivity and profitability may not be fully valued by investors.